Literature DB >> 15962289

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Andrea L Cox1, Timothy Mosbruger, Georg M Lauer, Drew Pardoll, David L Thomas, Stuart C Ray.   

Abstract

We comprehensively studied the cellular immune response during acute human hepatitis C virus (HCV) infection by monthly prospective sampling of persons at high risk of infection. In 19 of 23 subjects, interferon-gamma-secreting T cells specific for 1 or more peptides spanning the entire HCV polyprotein were detected 1 to 3 months after infection. The median time to development of interferon gamma responses to HCV peptides was 33 days (range, 29-50 days), and these responses peaked between 180 and 360 days. Nineteen subjects had sufficient follow-up to determine outcome, with 15 (79%) developing persistent viremia and 4 (21%) clearing viremia spontaneously. Of those with progression to chronic infection and detectable T cell responses, all lost recognition of one or more antigens recognized during acute infection, and the median reduction in the magnitude of responses was 85%. Most significantly, despite ongoing viremia, those who had persistent infection did not develop new epitope specificities after the first 6 months of infection. In conclusion, in most individuals, the CD8+ T cell responses generated early in HCV infection decline in peripheral blood and are not replaced with new responses. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.html).

Entities:  

Mesh:

Year:  2005        PMID: 15962289      PMCID: PMC2759395          DOI: 10.1002/hep.20749

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes.

Authors:  P Klenerman; R M Zinkernagel
Journal:  Nature       Date:  1998-07-30       Impact factor: 49.962

2.  Multiple sequence alignment with Clustal X.

Authors:  F Jeanmougin; J D Thompson; M Gouy; D G Higgins; T J Gibson
Journal:  Trends Biochem Sci       Date:  1998-10       Impact factor: 13.807

3.  Hepatitis C: global prevalence.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1997-11-14

4.  Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs.

Authors:  Y M Wang; S C Ray; O Laeyendecker; J R Ticehurst; D L Thomas
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 5.  Epidemiology of hepatitis C in the West.

Authors:  M J Alter
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

6.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

7.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.

Authors:  R S Garfein; M C Doherty; E R Monterroso; D L Thomas; K E Nelson; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

Review 10.  The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.

Authors:  S A Kalams; B D Walker
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  104 in total

Review 1.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

2.  Cellular immune responses against persistent hepatitis C virus: gone but not forgotten.

Authors:  P Klenerman; N Semmo
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

3.  PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection.

Authors:  Cheng J Ma; Lei Ni; Ying Zhang; C L Zhang; Xiao Y Wu; Antwan N Atia; Penny Thayer; Jonathan P Moorman; Zhi Q Yao
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

Review 4.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

5.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

6.  Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Authors:  Silvana Gaudieri; Andri Rauch; Lawrence P Park; Elizabeth Freitas; Susan Herrmann; Gary Jeffrey; Wendy Cheng; Katja Pfafferott; Kiloshni Naidoo; Russell Chapman; Manuel Battegay; Rainer Weber; Amalio Telenti; Hansjakob Furrer; Ian James; Michaela Lucas; Simon A Mallal
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

7.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

8.  Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs.

Authors:  Shadi Salloum; Cesar Oniangue-Ndza; Christoph Neumann-Haefelin; Laura Hudson; Silvia Giugliano; Marc aus dem Siepen; Jacob Nattermann; Ulrich Spengler; Georg M Lauer; Manfred Wiese; Paul Klenerman; Helen Bright; Norbert Scherbaum; Robert Thimme; Michael Roggendorf; Sergei Viazov; Joerg Timm
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.

Authors:  Shirin Ashraf; Katja Nitschke; Usama M Warshow; Collin R Brooks; Arthur Y Kim; Georg M Lauer; Theresa J Hydes; Matthew E Cramp; Graeme Alexander; Ann-Margaret Little; Robert Thimme; Christoph Neumann-Haefelin; Salim I Khakoo
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

Review 10.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.